Porvair Expands Its Operations at New Milton
News Feb 13, 2014
Porvair Filtration Group has announced the expansion of its UK facilities in New Milton near Christchurch. The new factory purchased this month will allow a consolidation of Porvair’s business in the UK and provides much needed manufacturing capacity to support the future growth of the business.
Porvair Filtration Group, whose parent company, Porvair plc, saw revenues grow by 10% last year, will consolidate its activities in the market for industrial filtration and separation products on the new site. Tom Liddell, Managing Director of Porvair Filtration Group commented, ‘At over 40,000 square feet, the new facility will allow us to integrate a number of activities within smaller units in the area, gaining efficiency in our operations and giving us space to sustain our growth. The investment is significant, but it is consistent with the sizeable growth opportunity we see for our products in the industrial process market.’
Porvair Filtration Group has supplied the process industry for over 25 years, with innovative and performance driven filtration equipment (elements, cartridges and vessels). The process industry demands filters that can withstand the most extreme and aggressive conditions of temperature, pressure and corrosion, whilst safeguarding operators and systems from particulates and ensuring environmental protection. Each filtration and separation requirement presents its own critical challenges and requires superior reliability, durability and a robust product construction. Porvair Filtration Group provide highly specialised filtration solutions for use throughout the manufacturing process and have proven filtration solutions for the production of chemicals such as nitric acid, maleic anhydride, caprolactum, hydrogen peroxide, sulphuric acid, phosphoric acid, magnesium nitrate, as well as HDPE and LLDPE. By using the latest in metallic filter media technology, Porvair are able to provide improved performance, and reduced plant operating costs, enabling longer campaigns and greater materials recovery.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
2nd AI Pharma Innovation: Drug Discovery 2019 Summit
Feb 27 - Feb 28, 2019
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
14th World Congress on Medicinal Chemistry and Drug Design
Jun 10 - Jun 11, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019